Immunological response in mice bearing LM3 breast tumor undergoing Pulchellin treatment
Carregando...
Fontes externas
Fontes externas
Data
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Biomed Central Ltd.
Springer Nature
Springer Nature
Tipo
Artigo
Direito de acesso
Acesso aberto
Fontes externas
Fontes externas
Resumo
Background: Ribosome-inactivating proteins (RIP) have been studied in the search for toxins that could be used as immunotoxins for cancer treatment. Pulchellin, a type 2 RIP, is suggested to induce immune responses that have a role in controlling cancer.Methods: The percentage of dendritic cells and CD4(+) and CD8(+) T cells in the spleen (flow cytometry), cytokines' release by PECs and splenocytes (ELISA) and nitric oxide production by PECs (Griess assay) were determined from tumor-bearing mice injected intratumorally with 0.1 ml of pulchellin at 0.75 mu g/kg of body weight. Statistical analysis was performed by one-way ANOVA with Tukey's post hoc test.Results: Pulchellin-treated mice showed significant immune system activation, characterized by increased release of IFN-gamma and Th2 cytokines (IL-4 and IL-10), while IL-6 and TGF-beta levels were decreased. There was also an increase in macrophage's activation, as denoted by the higher percentage of macrophages expressing adhesion and costimulatory molecules (CD54 and CD80, respectively).Conclusions: Our results suggest that pulchellin is promising as an adjuvant in breast cancer treatment.
Descrição
Palavras-chave
Idioma
Inglês
Citação
Bmc Complementary and Alternative Medicine. London: Biomed Central Ltd., v. 12, p. 6, 2012.
